Abstract
Programmed ventricular stimulation has dramatically advanced understanding of ventricular tachycardia after myocardial infarction. It remains an important tool for sudden cardiac death risk assessment in certain groups of patients. Its role in patients without infarct-related scar is less clear. Current role of programmed ventricular stimulation, invasive assessment of accessory pathway properties and HV interval measurement is discussed in detail.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
The induction of polymorphic VT with 3 extrastimuli counted as positive result, though VF still had to be induced with 1 or 2 extrastimuli to count as a positive result.
Abbreviations
- AAD:
-
Antiarrhythmic drugs
- ARVD:
-
Arrhythmogenic right ventricular dysplasia
- AV:
-
Atrioventricular
- CAD:
-
Coronary artery disease
- CASCADE:
-
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation
- CAST:
-
Cardiac Arrhythmia Suppression Trial
- CAST-II:
-
Cardiac Arrhythmia Suppression Trial II
- CL:
-
Cycle length
- DCM:
-
Dilated cardiomyopathy
- ERP:
-
Effective refractory period
- ESVEM:
-
Electrophysiologic Study versus Electrocardiographic Monitoring Trial
- HCM:
-
Hypertrophic cardiomyopathy
- ICD:
-
Implantable cardioverter defibrillator
- LV:
-
Left ventricle left ventricular
- LVEF:
-
Left ventricular ejection fraction
- MADIT:
-
Multicenter Automatic Defibrillator Implantation Trial
- MADIT-2:
-
Multicenter Automatic Defibrillator Implantation Trial II
- MI:
-
Myocardial infarction
- MUSTT:
-
Multicenter Unsustained Tachycardia Trial
- PVS:
-
Programmed ventricular stimulation
- RFA:
-
Radiofrequency ablation
- RV:
-
Right ventricle, or right ventricular
- RVA:
-
Right ventricular apex
- RVOT:
-
Right ventricular outflow tract
- SCD:
-
Sudden cardiac death
- SMVT:
-
Sustained monomorphic ventricular tachycardia
- TOF:
-
Tetralogy of Fallot
- VF:
-
Ventricular fibrillation
- VT:
-
Ventricular tachycardia
- WPW:
-
Wolff-Parkinson-White
References
Wellens HJ, Schuilenburg RM, Durrer D. Electrical stimulation of the heart in patients with ventricular tachycardia. Circulation. 1972;46:216–26.
Lin HT, Mann DE, Luck JC, Krafchek J, Magro SA, Sakun V, et al. Prospective comparison of right and left ventricular stimulation for induction of sustained ventricular tachycardia. Am J Cardiol. 1987;59:559–63.
Michelson EL, Spielman SR, Greenspan AM, Farshidi A, Horowitz LN, Josephson ME. Electrophysiologic study of the left ventricle: indications and safety. Chest. 1979;75:592–6.
Buxton AE, Fisher JD, Josephson ME, Lee KL, Pryor DB, Prystowsky EN, et al. Prevention of sudden death in patients with coronary artery disease: the multicenter unsustained tachycardia trial (MUSTT). Prog Cardiovasc Dis. 1993;36:215–26.
Hummel JD, Strickberger SA, Daoud E, Niebauer M, Bakr O, Man KC, et al. Results and efficiency of programmed ventricular stimulation with four extrastimuli compared with one, two, and three extrastimuli. Circulation. 1994;90:2827–32.
Denker S, Lehmann MH, Mahmud R, Gilbert C, Akhtar M. Facilitation of macroreentry within the His-Purkinje system with abrupt changes in cycle length. Circulation. 1984;69:26–32.
Niebauer M, Daoud E, Goyal R, Chan KK, Harvey M, Bogun F, et al. Use of isoproterenol during programmed ventricular stimulation in patients with coronary artery disease and nonsustained ventricular tachycardia. Am Heart J. 1996;131:516–8.
Morady F, DiCarlo L, Winston S, Davis JC, Scheinman MM. A prospective comparison of triple extrastimuli and left ventricular stimulation in studies of ventricular tachycardia induction. Circulation. 1984;70:52–7.
Morady F, DiCarlo Jr LA, Baerman JM, de Buitleir M. Comparison of coupling intervals that induce clinical and nonclinical forms of ventricular tachycardia during programmed stimulation. Am J Cardiol. 1986;57:1269–73.
Brugada P, Wellens HJ. Comparison in the same patient of two programmed ventricular stimulation protocols to induce ventricular tachycardia. Am J Cardiol. 1985;55:380–3.
Kennedy EE, Rosenfeld LE, McPherson CA, Stark SI, Batsford WP. Mechanisms and relevance of arrhythmias induced by high-current programmed ventricular stimulation. Am J Cardiol. 1986;57:598–603.
Weissberg PL, Broughton A, Harper RW, Young A, Pitt A. Induction of ventricular arrhythmias by programmed ventricular stimulation: a prospective study on the effects of stimulation current on arrhythmia induction. Br Heart J. 1987;58:489–94.
de Buitleir M, Morady F, DiCarlo Jr LA, Baerman JM, Krol RB. Immediate reproducibility of clinical and nonclinical forms of induced ventricular tachycardia. Am J Cardiol. 1986;58:279–82.
Lombardi F, Stein J, Podrid PJ, Graboys TB, Lown B. Daily reproducibility of electrophysiologic test results in malignant ventricular arrhythmia. Am J Cardiol. 1986;57:96–101.
McPherson CA, Rosenfeld LE, Batsford WP. Day-to-day reproducibility of responses to right ventricular programmed electrical stimulation: implications for serial drug testing. Am J Cardiol. 1985;55:689–95.
Rosenbaum MS, Wilber DJ, Finkelstein D, Ruskin JN, Garan H. Immediate reproducibility of electrically induced sustained monomorphic ventricular tachycardia before and during antiarrhythmic therapy. J Am Coll Cardiol. 1991;17:133–8.
Wilber DJ, Garan H, Finkelstein D, Kelly E, Newell J, McGovern B, et al. Out-of-hospital cardiac arrest. Use of electrophysiologic testing in the prediction of long-term outcome. N Engl J Med. 1988;318:19–24.
Steinbeck G, Andresen D, Bach P, Haberl R, Oeff M, Hoffmann E, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med. 1992;327:987–92.
Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N Engl J Med. 1999;341:1882–90.
Buxton AE, Lee KL, DiCarlo L, Gold MR, Greer GS, Prystowsky EN, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter unsustained tachycardia trial investigators. N Engl J Med. 2000;342:1937–45.
Daubert JP, Zareba W, Hall WJ, Schuger C, Corsello A, Leon AR, et al. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol. 2006;47:98–107.
Bhandari AK, Widerhorn J, Sager PT, Leon C, Hong R, Kotlewski A, et al. Prognostic significance of programmed ventricular stimulation in patients surviving complicated acute myocardial infarction: a prospective study. Am Heart J. 1992;124:87–96.
Bourke JP, Young AA, Richards DA, Uther JB. Reduction in incidence of inducible ventricular tachycardia after myocardial infarction by treatment with streptokinase during infarct evolution. J Am Coll Cardiol. 1990;16:1703–10.
Mittal S, Hao SC, Iwai S, Stein KM, Markowitz SM, Slotwiner DJ, et al. Significance of inducible ventricular fibrillation in patients with coronary artery disease and unexplained syncope. J Am Coll Cardiol. 2001;38:371–6.
Link MS, Saeed M, Gupta N, Homoud MK, Wang PJ, Estes III NA. Inducible ventricular flutter and fibrillation predict for arrhythmia occurrence in coronary artery disease patients presenting with syncope of unknown origin. J Cardiovasc Electrophysiol. 2002;13:1103–8.
Epstein AE, DiMarco JP, Ellenbogen KA, Estes 3rd NA, Freedman RA, Gettes LS, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408.
Kumar S, Sivagangabalan G, Choi MC, Eipper V, Thiagalingam A, Kovoor P. Long-term outcomes of inducible very fast ventricular tachycardia (cycle length 200–250 ms) in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2010;21:262–9.
Viskin S, Ish-Shalom M, Koifman E, Rozovski U, Zeltser D, Glick A, et al. Ventricular flutter induced during electrophysiologic studies in patients with old myocardial infarction: clinical and electrophysiologic predictors, and prognostic significance. J Cardiovasc Electrophysiol. 2003;14:913–9.
Richards DA, Cody DV, Denniss AR, Russell PA, Young AA, Uther JB. Ventricular electrical instability: a predictor of death after myocardial infarction. Am J Cardiol. 1983;51:75–80.
Bhandari AK, Au PK, Rose JS, Kotlewski A, Blue S, Rahimtoola SH. Decline in inducibility of sustained ventricular tachycardia from two to twenty weeks after acute myocardial infarction. Am J Cardiol. 1987;59:284–90.
Nogami A, Aonuma K, Takahashi A, Nitta J, Chun YH, Iesaka Y, et al. Usefulness of early versus late programmed ventricular stimulation in acute myocardial infarction. Am J Cardiol. 1991;68:13–20.
Kumar S, Sivagangabalan G, Zaman S, West EB, Narayan A, Thiagalingam A, et al. Electrophysiology-guided defibrillator implantation early after ST-elevation myocardial infarction. Heart Rhythm. 2010;7:1589–97.
Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8.
Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–36.
Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324:781–8.
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II investigators. N Engl J Med. 1992;327:227–33.
Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic study versus electrocardiographic monitoring investigators. N Engl J Med. 1993;329:445–51.
Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (the CASCADE study). Am J Cardiol. 1991;67:578–84.
Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation. 1993;87:562–72.
Moss AJ, Hall WJ, Cannom DS, Daubert JP, Higgins SL, Klein H, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter automatic defibrillator implantation trial investigators. N Engl J Med. 1996;335:1933–40.
Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.
Brembilla-Perrot B, Suty-Selton C, Alla F, Beurrier D, Houriez P, Claudon O, et al. Risk factors for cardiac mortality in cases of syncope with previous history of myocardial infarction. Arch Mal Coeur Vaiss. 2003;96:1181–6.
Brembilla-Perrot B, Suty-Selton C, Houriez P, Claudon O, Beurrier D, Terrier de la Chaise A. Value of non-invasive and invasive studies in patients with bundle branch block, syncope and history of myocardial infarction. Europace. 2001;3:187–94.
Gohlke-Barwolf C, Peters K, Petersen J, Samek L, Eschenbruch E, Birnbaum D, et al. Influence of aortic valve replacement on sudden death in patients with pure aortic stenosis. Eur Heart J. 1988;9(Suppl E):139–41.
Martinez-Rubio A, Schwammenthal Y, Schwammenthal E, Block M, Reinhardt L, Garcia-Alberola A, et al. Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and long-term follow-up. Circulation. 1997;96:500–8.
Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C, et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356:975–81.
Khairy P, Landzberg MJ, Gatzoulis MA, Lucron H, Lambert J, Marcon F, et al. Value of programmed ventricular stimulation after tetralogy of Fallot repair: a multicenter study. Circulation. 2004;109:1994–2000.
Khairy P. Programmed ventricular stimulation for risk stratification in patients with tetralogy of Fallot: a Bayesian perspective. Nat Clin Pract Cardiovasc Med. 2007;4:292–3.
Alexander ME, Walsh EP, Saul JP, Epstein MR, Triedman JK. Value of programmed ventricular stimulation in patients with congenital heart disease. J Cardiovasc Electrophysiol. 1999;10:1033–44.
Hsia HH, Callans DJ, Marchlinski FE. Characterization of endocardial electrophysiological substrate in patients with nonischemic cardiomyopathy and monomorphic ventricular tachycardia. Circulation. 2003;108:704–10.
Hsia HH, Marchlinski FE. Characterization of the electroanatomic substrate for monomorphic ventricular tachycardia in patients with nonischemic cardiomyopathy. Pacing Clin Electrophysiol. 2002;25:1114–27.
Soejima K, Stevenson WG, Sapp JL, Selwyn AP, Couper G, Epstein LM. Endocardial and epicardial radiofrequency ablation of ventricular tachycardia associated with dilated cardiomyopathy: the importance of low-voltage scars. J Am Coll Cardiol. 2004;43:1834–42.
Caceres J, Jazayeri M, McKinnie J, Avitall B, Denker ST, Tchou P, et al. Sustained bundle branch reentry as a mechanism of clinical tachycardia. Circulation. 1989;79:256–70.
Becker R, Haass M, Ick D, Krueger C, Bauer A, Senges-Becker JC, et al. Role of nonsustained ventricular tachycardia and programmed ventricular stimulation for risk stratification in patients with idiopathic dilated cardiomyopathy. Basic Res Cardiol. 2003;98:259–66.
Gonska BD, Bethge KP, Kreuzer H. Programmed ventricular stimulation in coronary artery disease and dilated cardiomyopathy: influence of the underlying heart disease on the results of electrophysiologic testing. Clin Cardiol. 1987;10:294–304.
Turitto G, Ahuja RK, Caref EB, el Sherif N. Risk stratification for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: role of programmed ventricular stimulation and the signal-averaged electrocardiogram. J Am Coll Cardiol. 1994;24:1523–8.
Brilakis ES, Shen WK, Hammill SC, Hodge DO, Rea RF, Lexvold NY, et al. Role of programmed ventricular stimulation and implantable cardioverter defibrillators in patients with idiopathic dilated cardiomyopathy and syncope. Pacing Clin Electrophysiol. 2001;24:1623–30.
Grimm W, Hoffmann J, Menz V, Luck K, Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. J Am Coll Cardiol. 1998;32:739–45.
Milner PG, DiMarco JP, Lerman BB. Electrophysiological evaluation of sustained ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. Pacing Clin Electrophysiol. 1988;11:562–8.
Poll DS, Marchlinski FE, Buxton AE, Doherty JU, Waxman HL, Josephson ME. Sustained ventricular tachycardia in patients with idiopathic dilated cardiomyopathy: electrophysiologic testing and lack of response to antiarrhythmic drug therapy. Circulation. 1984;70:451–6.
Turitto G, Ahuja RK, Bekheit S, Caref EB, Ibrahim B, el Sherif N. Incidence and prediction of induced ventricular tachyarrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:770–3.
Rolf S, Haverkamp W, Borggrefe M, Breithardt G, Bocker D. Induction of ventricular fibrillation rather than ventricular tachycardia predicts tachyarrhythmia recurrences in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillator for secondary prophylaxis. Europace. 2009;11:289–96.
Pogwizd SM. Nonreentrant mechanisms underlying spontaneous ventricular arrhythmias in a model of nonischemic heart failure in rabbits. Circulation. 1995;92:1034–48.
Pogwizd SM, McKenzie JP, Cain ME. Mechanisms underlying spontaneous and induced ventricular arrhythmias in patients with idiopathic dilated cardiomyopathy. Circulation. 1998;98:2404–14.
Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212–8.
Maron BJ, Shen WK, Link MS, Epstein AE, Almquist AK, Daubert JP, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000;342:365–73.
Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon III RO, Bonow RO, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy. A consecutive analysis in 155 patients. Circulation. 1989;80:1259–68.
Watson RM, Schwartz JL, Maron BJ, Tucker E, Rosing DR, Josephson ME. Inducible polymorphic ventricular tachycardia and ventricular fibrillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death. J Am Coll Cardiol. 1987;10:761–74.
Zhu DW, Sun H, Hill R, Roberts R. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. Pacing Clin Electrophysiol. 1998;21:299–302.
Hedman A, Hartikainen J, Vanninen E, Laitinen T, Jaaskelainen P, Laakso M, et al. Inducibility of life-threatening ventricular arrhythmias is related to maximum left ventricular thickness and clinical markers of sudden cardiac death in patients with hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene. J Mol Cell Cardiol. 2004;36:91–9.
Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological findings. Circulation. 1992;86:730–40.
Behr ER, Elliott P, McKenna WJ. Role of invasive EP testing in the evaluation and management of hypertrophic cardiomyopathy. Card Electrophysiol Rev. 2002;6:482–6.
Yamashiro S, Kuniyoshi Y, Miyagi K, Uezu T, Arakaki K, Koja K. Two cases of ventricular tachycardia with congenital left ventricular malformation in an adult. Ann Thorac Cardiovasc Surg. 2004;10:42–6.
Ellison KE, Friedman PL, Ganz LI, Stevenson WG. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia. J Am Coll Cardiol. 1998;32:724–8.
Marchlinski FE, Zado E, Dixit S, Gerstenfeld E, Callans DJ, Hsia H, et al. Electroanatomic substrate and outcome of catheter ablative therapy for ventricular tachycardia in setting of right ventricular cardiomyopathy. Circulation. 2004;110:2293–8.
Pezawas T, Stix G, Kastner J, Schneider B, Wolzt M, Schmidinger H. Ventricular tachycardia in arrhythmogenic right ventricular dysplasia/cardiomyopathy: clinical presentation, risk stratification and results of long-term follow-up. Int J Cardiol. 2006;107:360–8.
Corrado D, Leoni L, Link MS, Della BP, Gaita F, Curnis A, et al. Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Circulation. 2003;108:3084–91.
Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation. 2010;122:1144–52.
Sarabanda AV, Sosa E, Simoes MV, Figueiredo GL, Pintya AO, Marin-Neto JA. Ventricular tachycardia in Chagas’ disease: a comparison of clinical, angiographic, electrophysiologic and myocardial perfusion disturbances between patients presenting with either sustained or nonsustained forms. Int J Cardiol. 2005;102:9–19.
Silva RM, Tavora MZ, Gondim FA, Metha N, Hara VM, Paola AA. Predictive value of clinical and electrophysiological variables in patients with chronic chagasic cardiomyopathy and nonsustained ventricular tachycardia. Arq Bras Cardiol. 2000;75:33–47.
Grollier G, Galateau F, Scanu P, Commeau P, Voglimacci M, Bernard JP, et al. Cardiac sarcoidosis responsible for localized left ventricular ectasia and refractory ventricular tachycardia. Anatomoclinical study. Arch Mal Coeur Vaiss. 1990;83:561–4.
Jain A, Starek PJ, Delany DL. Ventricular tachycardia and ventricular aneurysm due to unrecognized sarcoidosis. Clin Cardiol. 1990;13:738–40.
Toda G, Iliev II, Kawahara F, Hayano M, Yano K. Left ventricular aneurysm without coronary artery disease, incidence and clinical features: clinical analysis of 11 cases. Intern Med. 2000;39:531–6.
Aizer A, Stern EH, Gomes JA, Teirstein AS, Eckart RE, Mehta D. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–82.
Furushima H, Chinushi M, Sugiura H, Kasai H, Washizuka T, Aizawa Y. Ventricular tachyarrhythmia associated with cardiac sarcoidosis: its mechanisms and outcome. Clin Cardiol. 2004;27:217–22.
Chinushi M, Mezaki T, Aoki Y, Nakagawa I, Washizuka T, Aizawa Y. Demonstration of transient entrainment in monomorphic sustained ventricular tachycardia associated with cardiac sarcoidosis. Jpn Circ J. 2000;64:635–7.
Noda T, Suyama K, Shimizu W, Satomi K, Otomo K, Okamura H, et al. Ventricular tachycardia with figure eight pattern originating from the right ventricle in a patient with cardiac sarcoidosis. Pacing Clin Electrophysiol. 2004;27:561–2.
Mezaki T, Chinushi M, Washizuka T, Furushima H, Chinushi Y, Ebe K, et al. Discrepancy between inducibility of ventricular tachycardia and activity of cardiac sarcoidosis. Requirement of defibrillator implantation for the inactive stage of cardiac sarcoidosis. Intern Med. 2001;40:731–5.
Mehta D, Mori N, Goldbarg SH, Lubitz S, Wisnivesky JP, Teirstein A. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43–8.
Bhandari AK, Shapiro WA, Morady F, Shen EN, Mason J, Scheinman MM. Electrophysiologic testing in patients with the long QT syndrome. Circulation. 1985;71:63–71.
Gasparini M, Priori SG, Mantica M, Coltorti F, Napolitano C, Galimberti P, et al. Programmed electrical stimulation in Brugada syndrome: how reproducible are the results? J Cardiovasc Electrophysiol. 2002;13:880–7.
Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation. 2003;108:3092–6.
Brugada P, Brugada R, Mont L, Rivero M, Geelen P, Brugada J. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol. 2003;14:455–7.
Brugada P, Geelen P, Brugada R, Mont L, Brugada J. Prognostic value of electrophysiologic investigations in Brugada syndrome. J Cardiovasc Electrophysiol. 2001;12:1004–7.
Priori SG, Napolitano C, Gasparini M, Pappone C, Della BP, Giordano U, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation. 2002;105:1342–7.
Eckardt L, Kirchhof P, Schulze-Bahr E, Rolf S, Ribbing M, Loh P, et al. Electrophysiologic investigation in Brugada syndrome; yield of programmed ventricular stimulation at two ventricular sites with up to three premature beats. Eur Heart J. 2002;23:1394–401.
Kanda M, Shimizu W, Matsuo K, Nagaya N, Taguchi A, Suyama K, et al. Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J Am Coll Cardiol. 2002;39:1799–805.
Eckardt L, Probst V, Smits JP, Bahr ES, Wolpert C, Schimpf R, et al. Long-term prognosis of individuals with right precordial ST-segment-elevation Brugada syndrome. Circulation. 2005;111:257–63.
Paul M, Gerss J, Schulze-Bahr E, Wichter T, Vahlhaus C, Wilde AA, et al. Role of programmed ventricular stimulation in patients with Brugada syndrome: a meta-analysis of worldwide published data. Eur Heart J. 2007;28:2126–33.
Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, et al. Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol. 2005;46:1712–20.
Buxton AE, Lee KL, Hafley GE, Wyse DG, Fisher JD, Lehmann MH, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation. 2002;106:2466–72.
Chen SA, Chiang CE, Tai CT, Cheng CC, Chiou CW, Lee SH, et al. Complications of diagnostic electrophysiologic studies and radiofrequency catheter ablation in patients with tachyarrhythmias: an eight-year survey of 3,966 consecutive procedures in a tertiary referral center. Am J Cardiol. 1996;77:41–6.
Voss F, Lu J, Schreiner KD, Bauer A, Becker R, Kubler W, et al. Evaluation of syncope in geriatric patients: normal values, complications and outcome of invasive electrophysiological study. Z Kardiol. 2000;89:1026–31.
Wagshal AB, Schuger CD, Habbal B, Mittleman RS, Huang SK. Invasive electrophysiologic evaluation in octogenarians: is age a limiting factor? Am Heart J. 1993;126:1142–6.
Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A, Wellens HJ. Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1995;76:492–4.
Munger TM, Packer DL, Hammill SC, Feldman BJ, Bailey KR, Ballard DJ, et al. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953–1989. Circulation. 1993;87:866–73.
Goudevenos JA, Katsouras CS, Graekas G, Argiri O, Giogiakas V, Sideris DA. Ventricular pre-excitation in the general population: a study on the mode of presentation and clinical course. Heart. 2000;83:29–34.
Attoyan C, Haissaguerre M, Dartigues JF, Le Metayer P, Warin JF, Clementy J. Ventricular fibrillation in Wolff-Parkinson-White syndrome. Predictive factors. Arch Mal Coeur Vaiss. 1994;87:889–97.
Fananapazir L, Packer DL, German LD, Greer GS, Gallagher JJ, Pressley JC, et al. Procainamide infusion test: inability to identify patients with Wolff-Parkinson-White syndrome who are potentially at risk of sudden death. Circulation. 1988;77:1291–6.
Klein GJ, Bashore TM, Sellers TD, Pritchett EL, Smith WM, Gallagher JJ. Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med. 1979;301:1080–5.
Boahene KA, Klein GJ, Sharma AD, Yee R, Fujimura O. Value of a revised procainamide test in the Wolff-Parkinson-White syndrome. Am J Cardiol. 1990;65:195–200.
Gaita F, Giustetto C, Riccardi R, Mangiardi L, Brusca A. Stress and pharmacologic tests as methods to identify patients with Wolff-Parkinson-White syndrome at risk of sudden death. Am J Cardiol. 1989;64:487–90.
Wellens HJ, Braat S, Brugada P, Gorgels AP, Bar FW. Use of procainamide in patients with the Wolff-Parkinson-White syndrome to disclose a short refractory period of the accessory pathway. Am J Cardiol. 1982;50:1087–9.
Medeiros A, Iturralde P, Guevara M, Mendoza C, Colin L. Sudden death in intermittent Wolff Parkinson White syndrome. Arch Cardiol Mex. 2001;71:59–65.
Scheinman MM, Weiss A, Kunkel F. His bundle recordings in patients with bundle branch block and transient neurologic symptoms. Circulation. 1973;48:322–30.
Scheinman MM, Peters RW, Modin G, Brennan M, Mies C, O’Young J. Prognostic value of infranodal conduction time in patients with chronic bundle branch block. Circulation. 1977;56:240–4.
McAnulty JH, Rahimtoola SH, Murphy E, DeMots H, Ritzmann L, Kanarek PE, et al. Natural history of “high-risk” bundle-branch block: final report of a prospective study. N Engl J Med. 1982;307:137–43.
Dhingra RC, Palileo E, Strasberg B, Swiryn S, Bauernfeind RA, Wyndham CR, et al. Significance of the HV interval in 517 patients with chronic bifascicular block. Circulation. 1981;64:1265–71.
Dhingra RC, Wyndham C, Bauernfeind R, Swiryn S, Deedwania PC, Smith T, et al. Significance of block distal to the his bundle induced by atrial pacing in patients with chronic bifascicular block. Circulation. 1979;60:1455–64.
Petrac D, Radic B, Birtic K, Gjurovic J. Prospective evaluation of infrahisal second-degree AV block induced by atrial pacing in the presence of chronic bundle branch block and syncope. Pacing Clin Electrophysiol. 1996;19:784–92.
Twidale N, Heddle WF, Ayres BF, Tonkin AM. Clinical implications of electrophysiology study findings in patients with chronic bifascicular block and syncope. Aust N Z J Med. 1988;18:841–7.
Twidale N, Heddle WF, Tonkin AM. Procainamide administration during electrophysiology study – utility as a provocative test for intermittent atrioventricular block. Pacing Clin Electrophysiol. 1988;11:1388–97.
Girard SE, Munger TM, Hammill SC, Shen WK. The effect of intravenous procainamide on the HV interval at electrophysiologic study. J Interv Card Electrophysiol. 1999;3:129–37.
Brignole M, Menozzi C, Moya A, Garcia-Civera R, Mont L, Alvarez M, et al. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation. 2001;104:2045–50.
Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol. 2002;40:1645–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Němec, J., Shen, WK. (2013). Invasive Electrophysiologic Testing: Role in Sudden Death Prediction. In: Gussak, I., Antzelevitch, C. (eds) Electrical Diseases of the Heart. Springer, London. https://doi.org/10.1007/978-1-4471-4978-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4471-4978-1_17
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-4977-4
Online ISBN: 978-1-4471-4978-1
eBook Packages: MedicineMedicine (R0)